Mixed
In people with suppressed HIV and metabolic dysfunction-associated fatty liver disease (MAFLD), adjunctive treatment with maraviroc, metformin, or their combination for 48 weeks does not significantly reduce liver fat fraction compared to antiretroviral therapy alone.
If you have HIV and fatty liver, adding maraviroc or metformin to your standard HIV treatment is unlikely to reduce the fat in your liver. The trial showed no significant benefit for liver fat reduction compared to just staying on your HIV medication. Focus on proven lifestyle strategies for metabolic health.
Contrary to our hypothesis, neither MVC, MET, or the combination significantly reduced liver fat as measured by MRPDFF compared to ART alone.
Why this rating
Randomized controlled trial with a factorial design, though underpowered due to lower-than-expected baseline liver fat.
Source
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV
Leanne McCabe et al. · AIDS · 2024
DOI 10.1097/qad.0000000000003947
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →